ETF Components for YOLO - AdvisorShares Pure Cannabis ETF


Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

Holdings

Symbol Grade Price % Change Allocation
MSOS F -2.63 39.73
HITI C -0.75 11.20
SNDL D 0.00 6.66
REFI A 0.50 3.98
JAZZ B 1.25 3.28
AFCG D 0.00 3.23
OGI F 0.66 3.09
TLRY F 2.29 2.02

Recent News for AdvisorShares Pure Cannabis ETF & its Holdings

Date Stock Title
Nov 23 TLRY Meta Faces Multibillion-Dollar Lawsuit As Supreme Court Dismisses Appeal In Cambridge Analytica Data Scandal
Nov 22 JAZZ ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run?
Nov 22 JAZZ Jazz Pharmaceuticals price target lowered to $163 from $166 at Piper Sandler
Nov 22 MSOS Marijuana Industry Could Stay in Limbo Under Trump
Nov 21 SNDL SNDL Appoints New Chief Information Officer and New President, Liquor Division
Nov 21 TLRY German Cannabis: 20 Tons, 10M Grams - And That's Only 0.3% Of The Market, What's Missing?
Nov 21 SNDL Cannabis Stocks Feel The Burn: Matt Gaetz Bows Out As Trump's Attorney General Nominee
Nov 21 MSOS Cannabis Stocks Feel The Burn: Matt Gaetz Bows Out As Trump's Attorney General Nominee
Nov 21 TLRY Cannabis Stocks Feel The Burn: Matt Gaetz Bows Out As Trump's Attorney General Nominee
Nov 21 TLRY Tilray Brands snapped six straight sessions of losses
Nov 21 MSOS Cannabis Stocks Drop on Matt Gaetz Withdrawal
Nov 21 TLRY Redhook Brewery and Montlake Futures Team Up to Launch Montlake Gameday Gold Lager, a New Craft Beer in Support of University of Washington Athletes
Nov 21 TLRY Tilray Brands Unveils 2024 Holiday Cannabis Gift Guide
Nov 21 JAZZ Zymeworks, Jazz Pharmaceuticals Receive FDA's Accelerated Approval for Ziihera to Treat Biliary Tract Cancer
Nov 21 TLRY Tilray Brands Gets Festive with its 2024 Holiday Beverage Gift Guide
Nov 21 JAZZ Jazz and Zymeworks announce FDA approval of cancer therapy Ziihera
Nov 21 JAZZ Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
Nov 20 TLRY Tilray Brands, Inc. (TLRY) Stock Moves -1.53%: What You Should Know
Nov 20 TLRY Prediction: Tilray Brands Won't Be a Cannabis Company in 5 Years
Nov 20 TLRY Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US
Cannabis and its various applications have been used throughout human civilization for over 5,000 years. As society, business and regulatory landscapes evolve in the 21st century, the upside potential of cannabis as an emerging investment avenue has arrived. The portfolio manager believes today’s new era can be viewed in similar regard to post-Prohibition, commencing a growing acknowledgement and understanding of cannabis and its uses among a mainstream audience. The industries that comprise the multi-billion dollar cannabis universe represent a new frontier, where proper caution and due diligence must be exercised surrounding its regulations and risks, in seeking attractive long-term cannabis investment opportunities. The AdvisorShares Pure Cannabis ETF (Ticker: YOLO) became the first actively managed ETF with a dedicated cannabis investment mandate domiciled in the United States. The AdvisorShares Pure Cannabis ETF, or YOLO, seeks long-term capital appreciation by investing in both domestic and foreign cannabis equity securities. YOLO is designed to fully-invest for pure cannabis exposure under the guidance of a deeply experienced portfolio management team navigating the emerging cannabis marketplace.
Exchange Traded Fund ETF Exchange Traded Funds Advisorshares Cannabis Portfolio Management Psychoactive Drugs Euphoriants Entheogens Medicinal Plants Cannabis Smoking Portfolio Manager
Back to the Main YOLO Page...